Enrolment complete in Vogenx’ Phase 2 Trial of mizagliflozin for post-bariatric hypoglycaemia
Vogenx has completed patient enrolment of a mid-Phase 2 clinical dose ranging study (VGX-001-012) evaluating mizagliflozin in patients...
Enrolment complete in Vogenx’ Phase 2 Trial of mizagliflozin for post-bariatric hypoglycaemia
LSG: The balance between superior weight loss and preventing the onset of reflux
No overall cost–benefit after RYGB versus SG among T2DM patients
Bariatric experts issue recommendations for procedure selection in class I and II obesity patients
Journal Watch 14/2/2024
Gastric bypass improves long-term T2DM remission even after weight recurrence
Intragastric expandable capsule results in clinically meaningful reduction in body weight